Notícias

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]

Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you hold ...

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]

Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.

The pharmaceutical icon's dividend yield has been pared back by the stock's recent rally, driven by a new growth initiative.

Retiring on dividends at 60 sounds straightforward until you realize the yield tier you choose today could mean the difference between an income stream that doubles over a decade and one that quietly erodes your nest egg.

A $425,000 nest egg can generate wildly different monthly paychecks depending on where you put it, but chasing the biggest number often destroys the very asset you need to last through your 70s.

Replicating a Social Security check with dividends sounds straightforward until you realize the yield you chase determines whether your income grows, stalls, or quietly disappears over the next two decades.

Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.

Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.

The yield you chase at 52 could quietly cannibalize the very nest egg you need at 62. Before you reach for the biggest monthly payout, understand the compounding trap hiding inside each income tier.

Chasing a $50,000 monthly dividend stream sounds like a math problem, but the yield you pick determines whether your portfolio funds four decades of freedom or quietly cannibalizes itself while the checks keep arriving.

A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.

Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company’s talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to other large...

If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.

A mix of high expectations, profit-taking, and a slight dip in valuations has sent S&P 500 stocks sputtering even after solid earnings reports.

The number that separates a comfortable retirement from a perpetual side hustle depends entirely on which yield tier you trust with your capital, and the answer surprises most income investors who assume bigger payouts always win.

Johnson and Johnson just committed over a billion dollars to flood the market with American-made contact lenses, but retirees banking on Medicare to share the cost are about to get a rude awakening at the pharmacy counter.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

An 8% yield looks like a shortcut to $80,000 a year without selling a single share, but the brokerage account tells a different story than the headline number does.